VolitionRx Gets Green Light For Nucleosome-Based Colorectal Cancer Test
Blood-based cancer diagnostics firm VolitionRx CE-marked a new colorectal cancer-screening test that has shown the potential to reduce unnecessary colonoscopies by up to 25% when combined with the fecal immunochemical test (FIT) score.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.